It is our pleasure to share with you our latest report on Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment.
The report provides market and competitive analysis of evolving therapeutic landscape of IBD while anticipating how the future treatment paradigm is likely to evolve.
Key Highlights of the Deck –
- Assessment of the evolving treatment paradigm: Explore the market trends and transition from conventional step-up approaches to a more aggressive top-down strategy
- Current landscape of targeted therapies: Insights into the dominance of biologics (anti-TNFs, integrin antagonists, interleukin inhibitors) and the emergence of novel small molecules (JAK inhibitors, S1P1 modulators and integrin antagonists)
- Emerging pipeline of novel therapeutics: Key trends on clinical and preclinical drug candidates with new mechanisms of action (MoA) that will potentially shape the future of IBD treatment
- Competitive landscape and M&A dynamics: Analysis of competitive dynamics across market leaders, their product portfolios and key strategic deals driving growth in the IBD space
You can download the presentation here